Vanguard Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $1.08B | Sell |
18,127,847
-454,738
| -2% | -$24.8M | 0.02% | 683 |
|
|
2025
Q3 | $1.01B | Sell |
18,582,585
-421,247
| -2% | -$24.1M | 0.02% | 704 |
|
|
2025
Q2 | $1.04B | Buy |
19,003,832
+620
| +0% | +$36.5K | 0.02% | 662 |
|
|
2025
Q1 | $1.34B | Sell |
19,003,212
-368,973
| -2% | -$24.8M | 0.02% | 558 |
|
|
2024
Q4 | $1.27B | Buy |
19,372,185
+93,531
| +0.5% | +$6.26M | 0.02% | 585 |
|
|
2024
Q3 | $1.36B | Buy |
19,278,654
+284,616
| +1% | +$23.8M | 0.02% | 574 |
|
|
2024
Q2 | $1.56B | Buy |
18,994,038
+876,930
| +5% | +$73M | 0.03% | 509 |
|
|
2024
Q1 | $1.58B | Buy |
18,117,108
+67,046
| +0.4% | +$6M | 0.03% | 516 |
|
|
2023
Q4 | $1.74B | Buy |
18,050,062
+348,852
| +2% | +$30.9M | 0.04% | 464 |
|
|
2023
Q3 | $1.57B | Sell |
17,701,210
-40,496
| -0.2% | -$3.6M | 0.04% | 464 |
|
|
2023
Q2 | $1.54B | Buy |
17,741,706
+208,460
| +1% | +$19.6M | 0.04% | 469 |
|
|
2023
Q1 | $1.7B | Buy |
17,533,246
+168,166
| +1% | +$17.4M | 0.04% | 438 |
|
|
2022
Q4 | $1.8B | Buy |
17,365,080
+256,791
| +2% | +$24.1M | 0.05% | 413 |
|
|
2022
Q3 | $1.45B | Buy |
17,108,289
+263,453
| +2% | +$23.5M | 0.04% | 441 |
|
|
2022
Q2 | $1.4B | Buy |
16,844,836
+342,593
| +2% | +$27.3M | 0.04% | 475 |
|
|
2022
Q1 | $1.27B | Buy |
16,502,243
+151,212
| +0.9% | +$12.7M | 0.03% | 553 |
|
|
2021
Q4 | $1.44B | Buy |
16,351,031
+44,474
| +0.3% | +$3.67M | 0.03% | 531 |
|
|
2021
Q3 | $1.26B | Buy |
16,306,557
+83,963
| +0.5% | +$6.62M | 0.03% | 561 |
|
|
2021
Q2 | $1.35B | Sell |
16,222,594
-131,755
| -0.8% | -$10.4M | 0.03% | 541 |
|
|
2021
Q1 | $1.23B | Sell |
16,354,349
-15,340
| -0.1% | -$1.25M | 0.03% | 548 |
|
|
2020
Q4 | $1.44B | Buy |
16,369,689
+34,253
| +0.2% | +$2.72M | 0.04% | 468 |
|
|
2020
Q3 | $1.24B | Sell |
16,335,436
-583,115
| -3% | -$59M | 0.04% | 452 |
|
|
2020
Q2 | $2.09B | Sell |
16,918,551
-37,499
| -0.2% | -$3.73M | 0.07% | 278 |
|
|
2020
Q1 | $1.43B | Buy |
16,956,050
+419,270
| +3% | +$36.1M | 0.06% | 335 |
|
|
2019
Q4 | $1.4B | Buy |
16,536,780
+54,336
| +0.3% | +$4.1M | 0.05% | 438 |
|
|
2019
Q3 | $1.11B | Buy |
16,482,444
+524,772
| +3% | +$40.4M | 0.04% | 486 |
|
|
2019
Q2 | $1.37B | Buy |
15,957,672
+247,798
| +2% | +$21.2M | 0.05% | 412 |
|
|
2019
Q1 | $1.4B | Buy |
15,709,874
+167,970
| +1% | +$15.6M | 0.05% | 394 |
|
|
2018
Q4 | $1.32B | Buy |
15,541,904
+537,134
| +4% | +$51.1M | 0.06% | 353 |
|
|
2018
Q3 | $1.46B | Buy |
15,004,770
+107,717
| +0.7% | +$10.8M | 0.06% | 391 |
|
|
2018
Q2 | $1.4B | Buy |
14,897,053
+104,839
| +0.7% | +$9.18M | 0.06% | 381 |
|
|
2018
Q1 | $1.2B | Buy |
14,792,214
+56,484
| +0.4% | +$4.85M | 0.05% | 415 |
|
|
2017
Q4 | $1.31B | Buy |
14,735,730
+185,050
| +1% | +$16.1M | 0.06% | 391 |
|
|
2017
Q3 | $1.35B | Buy |
14,550,680
+205,653
| +1% | +$18.2M | 0.06% | 354 |
|
|
2017
Q2 | $1.3B | Buy |
14,345,027
+642,623
| +5% | +$58.5M | 0.06% | 360 |
|
|
2017
Q1 | $1.2B | Buy |
13,702,404
+495,118
| +4% | +$44M | 0.06% | 357 |
|
|
2016
Q4 | $1.09B | Buy |
13,207,286
+977,000
| +8% | +$84M | 0.06% | 364 |
|
|
2016
Q3 | $1.13B | Buy |
12,230,286
+781,596
| +7% | +$73.6M | 0.07% | 338 |
|
|
2016
Q2 | $891M | Buy |
11,448,690
+346,369
| +3% | +$29.4M | 0.06% | 405 |
|
|
2016
Q1 | $916M | Sell |
11,102,321
-93,556
| -0.8% | -$7.61M | 0.06% | 372 |
|
|
2015
Q4 | $1.17B | Buy |
11,195,877
+355,727
| +3% | +$37.1M | 0.08% | 270 |
|
|
2015
Q3 | $1.14B | Buy |
10,840,150
+247,134
| +2% | +$33M | 0.08% | 255 |
|
|
2015
Q2 | $1.45B | Buy |
10,593,016
+571,997
| +6% | +$70.9M | 0.1% | 210 |
|
|
2015
Q1 | $1.25B | Buy |
10,021,019
+1,173,018
| +13% | +$124M | 0.08% | 259 |
|
|
2014
Q4 | $800M | Buy |
8,848,001
+356,963
| +4% | +$29.7M | 0.06% | 372 |
|
|
2014
Q3 | $613M | Buy |
8,491,038
+264,337
| +3% | +$17.4M | 0.05% | 448 |
|
|
2014
Q2 | $512M | Buy |
8,226,701
+195,583
| +2% | +$11.8M | 0.04% | 505 |
|
|
2014
Q1 | $548M | Buy |
8,031,118
+416,491
| +5% | +$30.7M | 0.05% | 458 |
|
|
2013
Q4 | $535M | Buy |
7,614,627
+366,316
| +5% | +$24.9M | 0.05% | 443 |
|
|
2013
Q3 | $523M | Buy |
7,248,311
+174,333
| +2% | +$11.6M | 0.05% | 424 |
|
|
2013
Q2 | $395M | Buy |
+7,073,978
| New | +$441M | 0.04% | 497 |
|
Other funds holding BMRN
Vanguard Group's BMRN Position: Q4 2025 in Review
Vanguard Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 2.4% in Q4 2025, selling an estimated $24.8M and leaving 18,127,847 shares worth $1.08B. The position accounts for 0.02% of the portfolio, ranked #683.
Vanguard Group first reported a position in BMRN in Q2 2013 and has held it in 51 quarters since. The position peaked at $2.09B in Q2 2020. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Vanguard Group held 18,127,847 shares of BioMarin Pharmaceuticals worth $1.08B as of Q4 2025.
- Vanguard Group sold 454,738 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $24.8M.
- BioMarin Pharmaceuticals made up 0.02% of Vanguard Group's portfolio in Q4 2025, its #683 holding.
- Vanguard Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's BioMarin Pharmaceuticals position peaked at $2.09B in Q2 2020.
- 538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.